# Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

> **NCT07012980** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT07012980
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07012980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07012980, "Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07012980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*